16-5888-38
antibody from Invitrogen Antibodies
Targeting: PDCD1LG2
B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2
Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 16-5888-38 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD273 (B7-DC) Monoclonal Antibody (MIH18), Functional Grade, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The MIH18 monoclonal antibody reacts with human B7-DC, also known as PD-L2. B7-DC, a recently identified member of the B7 family, has a predicted molecular weight of approximately 25 kDa and belongs to the Ig superfamily. B7-DC is primarily expressed by subpopulations of dendritic cells and monocytes/macrophages. Although B7-DC has structural and sequence similarities to the B7 family, it does not bind CD28/CTLA-4, rather it is a ligand for PD-1. The interactions between PD-1 and B7-DC/PD-L2 have been reported to be involved in costimulation or suppression of T cell proliferation depending on state of cellular activation. MIH18 is a useful tool for studies to elucidate the exact function of B7-DC/PD-L2 in APC/T cell interaction and to characterize the expression pattern of this molecule in humans. MIH18 is a blocking antibody.
- Antibody clone number
- MIH18
- Concentration
- 1 mg/mL
Submitted references Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.
Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Cytokine induced expression of programmed death ligands in human neutrophils.
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation.
TREM-2 mediated signaling induces antigen uptake and retention in mature myeloid dendritic cells.
Munoz O, Banga R, Schelling R, Procopio FA, Mastrangelo A, Nortier P, Ohmiti K, Daraspe J, Cavassini M, Fenwick C, Perez L, Perreau M
PLoS pathogens 2022 Jul;18(7):e1010673
PLoS pathogens 2022 Jul;18(7):e1010673
Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.
De Waele J, Marcq E, Van Audenaerde JR, Van Loenhout J, Deben C, Zwaenepoel K, Van de Kelft E, Van der Planken D, Menovsky T, Van den Bergh JM, Willemen Y, Pauwels P, Berneman ZN, Lardon F, Peeters M, Wouters A, Smits EL
Oncoimmunology 2018;7(3):e1407899
Oncoimmunology 2018;7(3):e1407899
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W
Journal of hematology & oncology 2018 Feb 6;11(1):16
Journal of hematology & oncology 2018 Feb 6;11(1):16
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions.
Gulati N, Suárez-Fariñas M, Correa da Rosa J, Krueger JG
F1000Research 2015;4:149
F1000Research 2015;4:149
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, Grutters J, Culver DA, Dworski R, Sheller J, Massion PP, Polosukhin VV, Johnson JE, Kaminski N, Wilkes DS, Oswald-Richter KA, Drake WP
American journal of respiratory and critical care medicine 2014 Sep 1;190(5):560-71
American journal of respiratory and critical care medicine 2014 Sep 1;190(5):560-71
Cytokine induced expression of programmed death ligands in human neutrophils.
Bankey PE, Banerjee S, Zucchiatti A, De M, Sleem RW, Lin CF, Miller-Graziano CL, De AK
Immunology letters 2010 Apr 8;129(2):100-7
Immunology letters 2010 Apr 8;129(2):100-7
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM
Journal of immunology (Baltimore, Md. : 1950) 2009 May 1;182(9):5240-9
Journal of immunology (Baltimore, Md. : 1950) 2009 May 1;182(9):5240-9
PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation.
Yang W, Li H, Chen PW, Alizadeh H, He Y, Hogan RN, Niederkorn JY
Investigative ophthalmology & visual science 2009 Jan;50(1):273-80
Investigative ophthalmology & visual science 2009 Jan;50(1):273-80
TREM-2 mediated signaling induces antigen uptake and retention in mature myeloid dendritic cells.
Radhakrishnan S, Arneson LN, Upshaw JL, Howe CL, Felts SJ, Colonna M, Leibson PJ, Rodriguez M, Pease LR
Journal of immunology (Baltimore, Md. : 1950) 2008 Dec 1;181(11):7863-72
Journal of immunology (Baltimore, Md. : 1950) 2008 Dec 1;181(11):7863-72
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of in vitro derived human dendritic cells with 0.25 µg of Mouse IgG1 Isotype Control Functional Grade Purified (Product # 16-4714-82) (open histogram) or 0.25 µg of Anti-Human CD273 (B7-DC) Functional Grade Purified followed by Anti-Mouse IgG Biotin (Product # 13-4013-85) and Streptavidin PE (Product # 12-4317-87) (filled histogram). Total viable cells were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL